A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cancer (TroFuse-020/GOG-3101/ENGOT-cx20)

UVA Tracking #
301408
Principal Investigator
Linda R Duska
Contact
Contact Phone
Official Trial Title
A Phase 3 Randomized, Active-controlled, Open-label, Multicenter Study to Compare the Efficacy and Safety of MK-2870 Monotherapy Versus Treatment of Physician’s Choice as Second-line Treatment for Participants with Recurrent or Metastatic Cervical Cance
Study Description

The University of Virginia seeks adult women ages 18 years and older with recurrent or metastatic cervical cancer.

You may be eligible for this study if:
• You have squamous cell carcinoma, adenosquamous carcinoma, or adenocarcinoma of the cervix
• You have had one or more prior lines of systemic platinum chemotherapy and prior immunotherapy

You will be randomized (assigned by chance) to one of two treatment arms,
• Arm 1: MK2870 4mg/kg administered intravenously
• Arm2: Treatment of Physician’s choice consisting of one of the following: Pemetrexed, Tisotumab Vedotin, Topotecan, Vinorelbine, Gemcitabine, Irinotecan.

This study involves blood draw, imaging of the chest, abdomen and pelvis, electrocardiogram (ECG), Echocardiogram (ECHO) and archival tissue collection.

Study-related procedures that are being done beyond your standard of care will be provided at no cost to you or your insurance.

Compensation

No Compensation